News
Novo Nordisk (NYSE:NVO) is one of the most profitable value stocks to buy according to analysts. On July 25, Novo Nordisk ...
The review for IOA began on 23 December 2009 with an active review time of 210 days.The Committee gave also a positive opinion for Cinryze (C1 inhibitor, human), an orphan medicine from ViroPharma ...
Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...
The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS, July 25 ...
3d
Pharmaceutical Technology on MSNGilead wins positive European approval opinion for twice-yearly HIV injection
"Gilead wins positive European approval opinion for twice-yearly HIV injection" was originally created and published by ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen ...
Basel: Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
The review for IOA began on 23 December 2009 with an active review time of 210 days.The Committee gave also a positive opinion for Cinryze (C1 inhibitor, human), an orphan medicine from ViroPharma ...
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU Provided by PR Newswire Feb 28, 2025 5:11am ...
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 15-18 November 2010Positive opinion for a new medicine adoptedThe Committee adopted a positive opinion recommending ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results